Grufity logoGrufity logo

ICU Medical Inc Stock Research

ICUI

164.96USD+0.87(+0.53%)Market Closed

Market Summary

USD164.96+0.87
Market Closed
0.53%

ICUI Alerts

ICUI Stock Price

ICUI RSI Chart

ICUI Valuation

Market Cap

4.0B

Price/Earnings (Trailing)

-53.25

Price/Sales (Trailing)

1.73

EV/EBITDA

83.58

Price/Free Cashflow

-25.95

ICUI Price/Sales (Trailing)

ICUI Profitability

Operating Margin

31.04%

EBT Margin

-5.44%

Return on Equity

-3.55%

Return on Assets

-1.65%

Free Cashflow Yield

-3.85%

ICUI Fundamentals

ICUI Revenue

Revenue (TTM)

2.3B

Revenue Y/Y

69.74%

Revenue Q/Q

-3.32%

ICUI Earnings

Earnings (TTM)

-74.3M

Earnings Y/Y

-177.97%

Earnings Q/Q

-17.63%

Price Action

52 Week Range

128.90233.88
(Low)(High)

Last 7 days

5.6%

Last 30 days

-2.1%

Last 90 days

4.8%

Trailing 12 Months

-25.9%

ICUI Financial Health

Current Ratio

2.5

ICUI Investor Care

Shares Dilution (1Y)

13.03%

Diluted EPS (TTM)

-3.11

Peers (Alternatives to ICU Medical)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
108.0B
18.4B
9.81% 7.15%
45.81
5.86
7.84% 18.25%
89.4B
6.2B
12.38% -15.32%
67.62
14.37
8.97% -22.43%
71.6B
12.7B
6.86% 12.96%
102.61
5.65
6.68% -32.95%
70.1B
19.0B
7.04% -3.24%
43.54
3.69
-0.43% -8.78%
50.3B
5.4B
3.61% -29.72%
33.07
9.35
2.86% 1.25%
MID-CAP
7.2T
489.7M
14.55% 4.57%
82.2K
16.8K
106.51% 2464.23%
10.6B
847.1M
7.86% 25.46%
-5.3K
12.54
13.32% -137.89%
5.6B
1.0B
-2.14% -23.23%
32.76
5.52
6.76% 24.45%
3.7B
410.9M
4.99% -21.24%
-32.24
9.11
27.29% -14.60%
2.6B
801.2M
10.62% -65.08%
-27.7
3.27
14.00% -707.69%
SMALL-CAP
1.7B
350.9M
3.38% 35.65%
-10.93
4.74
44.26% -5.42%
1.5B
138.6M
-18.17% -5.23%
-27.28
10.83
36.62% -10.44%
1.4B
820.0M
5.46% -11.22%
27.4
1.69
10.13% 701.59%
833.4M
239.8M
0.46% -12.12%
-22.01
3.47
-4.74% -31.15%

Financials for ICU Medical

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue11.6%2,2802,0431,7811,5411,316
Gross Profit7.3%698650592548491
Operating Expenses10.7%741669572493368
  S&GA Expenses11.2%608547468383303
  R&D Expenses12.4%93.0083.0072.0061.0047.00
EBITDA-65.5%45.00130151159-
EBITDA Margin-69.1%0.02*0.06*0.08*0.10*-
Earnings Before Taxes-175.6%-123-44.9724.00--
EBT Margin10.4%-0.05*-0.06*-0.03*0.02*-
Interest Expenses-226.3%-66.3753.0032.0015.002.00
Net Income-91.3%-74.29-38.835.0041.00103
Net Income Margin-71.4%-0.03*-0.02*0.00*0.03*-
Free Cahsflow-122.2%-152-68.5912.00137-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.5%4,5164,4504,5904,7471,881
  Current Assets3.0%1,2351,1991,1901,1741,030
    Cash Equivalents-14.4%209244256329553
  Inventory11.3%696625583536290
  Net PPE-3.1%636656668674468
  Goodwill5.8%1,4491,3701,4211,52743.00
  Current Liabilities1.1%495489486494201
    LT Debt, Current21.8%30.0024.0019.0014.00-
    LT Debt, Non Current-0.4%1,6301,6361,642--
Shareholder's Equity3.8%2,0902,0132,0862,1791,616
  Retained Earnings-1.8%838853866874912
  Additional Paid-In Capital0.6%1,3311,3231,3101,306721
Accumulated Depreciation-437----
Shares Outstanding0.3%24.0024.0024.0021.00-
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-379.8%-62.1322.0099.00215268
  Share Based Compensation-1.8%36.0037.0034.0033.0027.00
Cashflow From Investing0.5%-1,909-1,918-1,926-1,939-90.69
Cashflow From Financing0.3%1,6371,6321,6311,635-16.87
  Buy Backs30.6%11.008.00---

Risks for ICUI

What is the probability of a big loss on ICUI?

68.5%


Probability that ICU Medical stock will be more than 20% underwater in next one year

49.2%


Probability that ICU Medical stock will be more than 30% underwater in next one year.

29.2%


Probability that ICU Medical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ICUI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ICU Medical was unfortunately bought at previous high price.

Drawdowns

Returns for ICUI

Cumulative Returns on ICUI

10.9%


10-Year Cumulative Returns

7.0%


7-Year Cumulative Returns

-8.1%


5-Year Cumulative Returns

-6.5%


3-Year Cumulative Returns

What are the long-term rolling returns for ICUI?

FIve years rolling returns for ICU Medical.

Annualized Returns

Which funds bought or sold ICUI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
reduced
-1.68
55,302
2,020,780
0.02%
2023-03-17
American Portfolios Advisors
unchanged
-
-690
7,530
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-28.89
-679,555
1,969,440
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-0.96
6,000
177,000
-%
2023-02-28
Voya Investment Management LLC
reduced
-3.14
7,424
578,424
-%
2023-02-24
SRS Capital Advisors, Inc.
unchanged
-
-370
630
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
21,000
477,000
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-98,000
-
-%
2023-02-21
KB FINANCIAL PARTNERS, LLC
reduced
-20.37
-1,000
7,000
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
added
11.25
2,411,850
17,181,800
0.03%

1–10 of 49

Latest Funds Activity

Are funds buying ICUI calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ICUI
No. of Funds

ICU Medical News

Nasdaq

Unusual Call Option Trade in ICU Medical (ICUI) Worth $1110.00K.

Nasdaq,
2 days ago

Investing News Network

Pfizer Invests $43 Billion to Battle Cancer.

Investing News Network,
19 days ago

Investing News Network

Yahoo Finance

Schedule 13G FIlings of ICU Medical

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
t. rowe price investment management, inc.
10.1%
2,423,228
SC 13G/A
Feb 10, 2023
janus henderson group plc
10.7%
2,557,226
SC 13G/A
Feb 09, 2023
vanguard group inc
8.77%
2,104,172
SC 13G/A
Feb 06, 2023
wellington management group llp
9.87%
2,366,386
SC 13G
Jan 31, 2023
blackrock inc.
7.5%
1,787,807
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
12.8%
2,725,540
SC 13G/A
Feb 10, 2022
vanguard group inc
9.18%
1,950,253
SC 13G/A
Feb 10, 2022
janus henderson group plc
10.8%
2,294,880
SC 13G/A
Feb 01, 2022
blackrock inc.
7.9%
1,686,855
SC 13G/A
Jan 12, 2022
smiths group international holdings ltd
10.5%
2,500,000
SC 13D

ICUI Fair Value

ICU Medical fair value in different scenarios

The table shows the Fair Value estimates for ICU Medical for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

95.70

-41.99%

161.38

-2.17%

313.85

90.26%

586.11

255.30%

985.35

497.33%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical ICU Medical Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of ICU Medical

View All Filings
Date Filed Form Type Document
Mar 15, 2023
S-8
Employee Benefits Plan
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 03, 2023
S-3ASR
S-3ASR
Feb 27, 2023
8-K
Current Report
Feb 27, 2023
10-K
Annual Report
Feb 14, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for ICUI

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-08
Woolson Daniel
sold (taxes)
-139,616
156
-894
vp, gm-infusion capital
2023-03-08
Bonnell Brian Michael
sold (taxes)
-181,626
156
-1,163
chief financial officer
2023-03-08
Voigtlander Christian B.
acquired
-
-
2,209
chief operating officer
2023-03-08
Voigtlander Christian B.
sold (taxes)
-181,626
156
-1,163
chief operating officer
2023-03-08
Jain Vivek
sold (taxes)
-207,550
156
-1,329
chairman and ceo
2023-03-08
Woolson Daniel
acquired
-
-
2,020
vp, gm-infusion capital
2023-03-08
Sanzone Virginia Ruth
sold (taxes)
-186,779
156
-1,196
vp, general counsel
2023-03-08
Sanzone Virginia Ruth
acquired
-
-
2,272
vp, general counsel
2023-03-08
Jain Vivek
acquired
-
-
2,525
chairman and ceo
2023-03-08
Bonnell Brian Michael
acquired
-
-
2,209
chief financial officer

1–10 of 50

Vivek Jain
8500
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

ICUI Income Statement

2022-12-31
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
REVENUES:   
Revenues$ 2,279,997$ 1,316,308$ 1,271,004
Cost of Goods Sold1,582,236824,818809,507
Gross profit697,761491,490461,497
OPERATING EXPENSES:   
Selling, general and administrative608,345302,583283,953
Research and development92,98447,49842,948
Restructuring, strategic transaction and integration expenses71,42118,03728,409
Change in fair value of contingent earn-out(32,091)09,000
Contractsettlements0127(975)
Total operating expenses740,659368,245363,335
Income from operations(42,898)123,24598,162
Interest Income (Expense), Net(66,375)1,9821,924
OTHER INCOME,NET(5,136)(2,041)(2,592)
Income before income taxes(114,409)123,18697,494
Provision for income taxes40,123(20,051)(10,624)
Net Income$ (74,286)$ 103,135$ 86,870
Basic$ (3.11)$ 4.86$ 4.16
Diluted$ (3.11)$ 4.74$ 4.02
WEIGHTED AVERAGE NUMBER OF SHARES   
Basic (in shares)23,86821,20620,907
Diluted (in shares)23,86821,78121,591

ICUI Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
CURRENT ASSETS:  
Cash and cash equivalents$ 208,784$ 552,827
Short-term investment securities4,22414,420
TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES213,008567,247
Accounts receivable, net of allowance for doubtful accounts of $8,530 at December 31, 2022 and $7,038 at December 31, 2021221,719105,894
Inventories696,009290,235
Prepaid income taxes15,52819,586
Prepaid expenses and other current assets88,93246,847
Total current assets1,235,1961,029,809
PROPERTY, PLANT AND EQUIPMENT, net636,113468,365
Operating Lease, Right-of-Use Assets74,86439,847
Long-term Investment Securities5164,620
GOODWILL1,449,25843,439
INTANGIBLE ASSETS, net982,766188,311
Deferred Income Tax Assets, Net31,46642,604
Other Assets105,46263,743
TOTAL ASSETS4,515,6411,880,738
CURRENT LIABILITIES:  
Accounts payable215,90281,128
Accrued liabilities242,769118,195
Long-Term Debt, Current Maturities29,6880
Accrued Income Taxes, Current6,2001,454
Total current liabilities494,559200,777
Contingent earn-out liability, Noncurrent25,5722,589
Long-Term Debt, Noncurrent1,623,6750
Other long-term Liabilities114,10441,830
Deferred Income Tax Liabilities, Net126,0071,490
Accrued Income Taxes, Noncurrent41,79618,021
COMMITMENTS AND CONTINGENCIES00
STOCKHOLDERS' EQUITY:  
Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none00
Common stock, $0.10 par value - Authorized-80,000 shares; Issued 23,995 and 21,280 shares at December 31, 2022 and 2021, respectively, and outstanding 23,993 and 21,280 shares at December 31, 2022 and 2021, respectively.2,3992,128
Additional paid-in capital1,331,249721,412
Treasury Stock, Value(243)(27)
Retained earnings837,501911,787
Accumulated other comprehensive loss(80,978)(19,269)
Total stockholders' equity2,089,9281,616,031
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 4,515,641$ 1,880,738